This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
All You Need to Know About EUROFINS SCIENT (ERFSF) Rating Upgrade to Buy
by Zacks Equity Research
EUROFINS SCIENT (ERFSF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
EUROFINS SCIENT (ERFSF) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
EUROFINS SCIENT (ERFSF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Industry Outlook Highlights: Avantor, Eurofins Scientific, GoodRx Holdings, Apollo Medical and COMPASS Pathways
by Zacks Equity Research
Zacks Industry Outlook Highlights: Avantor, Eurofins Scientific, GoodRx Holdings, Apollo Medical and COMPASS Pathways
5 Top Medical Services Stocks to Beat COVID-Led Industry Challenges
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Services industry. AVTR, ERFSF, GDRX, AMEH and CMPS are poised to gain.
What Makes EUROFINS SCIENT (ERFSF) a Good Fit for "Trend Investing"
by Zacks Equity Research
EUROFINS SCIENT (ERFSF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Avantor, Inc. (AVTR) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
EUROFINS SCIENT (ERFSF) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
EUROFINS SCIENT (ERFSF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for March 25th
by Zacks Equity Research
OMP, PBFX, WRLD, ERFSF, and UBAB have been added to the Zacks Rank #1 (Strong Buy) List on March 25, 2021.
ERFSF or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Amedisys, Select Medical Holdings, LHC, Eurofins Scientific and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amedisys, Select Medical Holdings, LHC, Eurofins Scientific and DaVita
5 Healthcare Stocks to Keep the Winning Streak Alive in 2020
by Sapna Bagaria
Increasing incidence of chronic diseases, aging U.S. population, innovation and consolidation will drive the healthcare industry's growth in 2020.
ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
Is EUROFINS SCIENT (ERFSF) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
ERFSF or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
ERFSF vs. ICLR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. ICLR: Which Stock Is the Better Value Option?
ERFSF vs. ICLR: Which Stock Is the Better Value Option?
by Zacks Equity Research
ERFSF vs. ICLR: Which Stock Is the Better Value Option?